|
| Status |
Public on Aug 02, 2024 |
| Title |
Targeting RBM39 for Improved Outcomes as a Novel Therapeutic Strategy in T-cell acute lymphoblastic leukemia |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Indisulam demonstrates significant antineoplastic properties in the context of T-cell acute lymphoblastic leukemia (T-ALL). Its effectiveness is primarily due to the degradation of RBM39, attenuating cell proliferation, promoting apoptosis and interfering with cell cycle progression in vitro, while facilitating tumor remission in T-ALL in vivo models.
|
| |
|
| Overall design |
mRNA profiles of J.gamma1 cells treated with 5μM indisulam or DMSO for 16h were generated by RNA sequencing, in double, using Illumina NovaSeq6000.
|
| |
|
| Contributor(s) |
Ji T, Lu J, Pan J |
| Citation(s) |
39044280 |
| |
| Submission date |
Apr 05, 2024 |
| Last update date |
Aug 02, 2024 |
| Contact name |
Zimu Zhang |
| Organization name |
Children’s Hospital of Soochow University
|
| Street address |
Zhongnan Street
|
| City |
Suzhou |
| State/province |
Jiangsu |
| ZIP/Postal code |
215000 |
| Country |
China |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (4)
|
|
| Relations |
| BioProject |
PRJNA1096684 |
Less...
More...